BRIEF—New CEO to lead viral vector push at Oxford Biomedica

Rentschler Biopharma chief executive Frank Mathias is to leave his post in order to take the reins at British cell and gene therapy company Oxford Biomedica.

Dr Mathias, who has led the German contract development and manufacturing organization (CDMO) since 2016, will assume his new post in March 2023.

In a statement, Oxford Biomedica noted that Dr Mathias has overseen a tripling of revenues at Rentschler, increasing efficiencies and enhancing profitability, among other accomplishments.

With over three decades of industry experience, he has also served in senior roles at leading global drugmakers including Amgen, Servier and Hoechst.

Chairperson Roch Doliveux said Dr Mathias would help “implement our strategy of becoming an innovative global viral vector leader.”